EP Patent

EP1103545A1 — 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide

Assigned to F Hoffmann La Roche AG · Expires 2001-05-30 · 25y expired

What this patent protects

The invention relates to the compound of the formula which is 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolylpyridin-3-yl)-isobutyramide. It has been found that this compound has a high affinity to the NK-1 receptor and it is therefore useful in …

USPTO Abstract

The invention relates to the compound of the formula which is 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolylpyridin-3-yl)-isobutyramide. It has been found that this compound has a high affinity to the NK-1 receptor and it is therefore useful in the treatment of diseases, which relate to this receptor.

Drugs covered by this patent

fosnetupitant-chloride-hydrochloride (FOSNETUPITANT CHLORIDE HYDROCHLORIDE)

Patent Metadata

Patent number: EP1103545A1
Jurisdiction: EP
Classification: —
Expires: 2001-05-30
Drug substance claim: No
Drug product claim: No
Assignee: F Hoffmann La Roche AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.